TYME News and Press, Tyme Technologies Inc. From 09/15/20

Marinus Pharmaceuticals (NASDAQ: MRNS )   +61%  after ganaxolone successful in pivot study in rare type of epilepsy. More news on: Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Tiziana Life Sciences PLC, Stocks on the move, , Read more ...

The Phase II Prostate Cancer study demonstrated that oral SM-88 (racemetyrosine) was associated with disease control while maintaining QOL; More than 450,000 of these patient cases annually in U.S. alone Based on study results, SM-88 may have a clinically meaningful role in postpon...

Tyme Technologies, Inc. (NASDAQ:TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership team will present at the BioNJ 10 th Annual BioPartnering Conference on Tuesday, October 6, 2020. The Company will present it...

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020. The Company will pr...

Tyme Technologies ( TYME -2.4% )   announces offer and sale of up to 2.17M common shares, issuable upon the exercise of the warrants at an exercise price of $1.80 per share, expiring on April 2, 2024. More news on: Tyme Technologies, Inc., Healthcare stocks news, , Stock...

Akebia Therapeutics (NASDAQ: AKBA )   -69%  after vadadustat misses safety endpoints in late-stage studies in CKD anemia. More news on: Akebia Therapeutics, Inc., Zuora, Inc., PagerDuty, Inc., Stocks on the move, , Read more ...

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will participate at the H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15, 2020. The Compan...

Tyme Technologies ( TYME +2.1% ) has announced to initiate a proof-of-concept Respond trial to investigate its TYME-19 metabolic agent as a therapy against Covid-19. More news on: Tyme Technologies, Inc., Healthcare stocks news, Read more ...

Tyme Technologies (NASDAQ: TYME ) +29% as oncology research reveals potential new oral therapy TYME-19 in the fight against COVID-19. More news on: Tyme Technologies, Inc., SCWorx Corp., Immunic, Inc., Stocks on the move, , Read more ...

TYME-19 is an oral synthetic bile acid that has demonstrated broad spectrum antiviral activity as well as efficacy against COVID-19 in preclinical studies Initiating proof-of-concept RESPOnD trial to investigate TYME-19 for safety and efficacy in recently diagnosed, symptomatic COVID-1...